Shanghai AbelZeta Ltd.

Shanghai AbelZeta Ltd., operating as AbelZeta Pharma, is a global cell therapy company headquartered in Shanghai, China. The company focuses on discovering, developing, and manufacturing innovative T-cell-based therapeutics to address unmet medical needs across hematologic malignancies, inflammatory and immunological diseases, and solid tumors. Its core platform is Chimeric Antigen Receptor (CAR)-T cell therapy, designed to empower the immune system in a personalized fight against cancer and inflammatory conditions. AbelZeta traces its clinical origins to 2015, when it treated its first oncology patient. Since then, the company has built a pipeline of best-in-class and best-in-disease potential candidates. A major milestone came in 2023, when it licensed two CD20-directed autologous CAR-T therapies to Janssen Biotech, a subsidiary of Johnson & Johnson. This partnership reflects AbelZeta's strategy of leveraging multinational pharmaceutical companies to accelerate global clinical development and maximize worldwide patient accessibility. The company emphasizes rapid proof-of-concept testing through investigator-initiated trials to de-risk and improve drug candidate selection. Its stated core strengths include proven target and optimal design, exceptional early clinical results, partnered lead programs, and an in-house platform capable of targeting both cancer and inflammatory and immunological (I&I) diseases. AbelZeta positions itself as a global leader in cell therapy, with operations and partnerships extending beyond China.

AbelZeta Pharma began its clinical journey in 2015 with the treatment of its first oncology patient. Over more than 14 years of optimizing its core strengths, the company has built a pipeline of best-in-class and best-in-disease potential candidates in cell therapy. Its approach centers on rapidly advancing innovative T-cell immunotherapies by leveraging proof-of-concept data from early-stage clinical trials, often through investigator-initiated trials, to de-risk and improve the efficiency of drug candidate selection. A defining moment came in 2023, when AbelZeta licensed two CD20-directed autologous CAR-T therapies to Janssen Biotech, a Johnson & Johnson company. This partnership was intended to leverage Janssen's expertise in clinical development and global commercialization, aligning with AbelZeta's goal of maximizing worldwide patient accessibility through multinational pharmaceutical partners. The company has continued to develop its in-house platform to facilitate multiple cell therapies targeting both cancer and inflammatory and immunological diseases. As of its public communications, AbelZeta describes itself as a global cell therapy leader with operations and partnerships extending beyond China.

• 2023

  Licensed two CD20-directed autologous CAR-T therapies to Janssen Biotech.

• 2015

  Treated first oncology patient.

Global cell therapy leader focused on innovative T-cell-based therapeutics for hematologic malignancies, inflammatory and immunological diseases, and solid tumors.

• CD20-directed autologous CAR-T therapies

  Two CAR-T therapies licensed to Janssen Biotech in 2023.

1. 1AbelZeta Pharma | Pioneering T Cell-Based Therapeutics for Cancer & Immunological Diseasesabelzeta.com
2. 2Our Story | AbelZeta Pharmaabelzeta.com
3. 3Shanghai AbelZeta Ltd. (China) - Wikidatawikidata.org